BridgeBio, which already owns about 66 percent of Eidos, had initially offered to buy the company in August, but the proposed deal was rejected. Eidos is developing a drug in the competitive ATTR space.
The company, which builds subsidiary companies centered around genetically driven diseases, said it would trade on the Nasdaq under the ticker symbol BBIO.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
The firm will follow a model similar to that of BridgeBio, partnering with scientific researchers and launching companies to develop and commercialize their products.